Related Experiment Video

Updated: Apr 18, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K

[Mitochondrial estrogen receptor β inhibits non-small cell lung cancer cell apoptosis via interaction with Bad]

Qiang Xie1, Zuoping Huang, Ying Liu

  • 1Armed Police Corps Hospital of Guangdong Province, Guangzhou 510507 China.E-mail: doctorxie@126.com.

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|January 24, 2015
PubMed
Abstract

Insights

Mitochondrial estrogen receptor β (ERβ) in non-small cell lung cancer cells suppresses apoptosis by interacting with the Bad protein. This finding highlights ERβ as a potential therapeutic target for lung cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cellular Signaling

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
  • Apoptosis regulation is crucial in cancer therapy, but resistance mechanisms are common.
  • Estrogen receptor β (ERβ) has been implicated in various cancers, with its role in NSCLC apoptosis still under investigation.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which mitochondrial ERβ influences apoptosis in NSCLC cells.
  • To investigate the interaction between mitochondrial ERβ and pro-apoptotic proteins in response to chemotherapy.

Main Methods:

  • Confirmed mitochondrial localization of ERβ in NSCLC cell lines (A549, 201T) via immunofluorescence and Western blotting.
  • Assessed apoptosis changes in response to cisplatin and STS with ERβ overexpression or knockdown.
  • Evaluated ERβ-Bad protein interactions using co-immunoprecipitation and Western blotting.

Main Results:

  • ERβ was successfully localized to mitochondria in NSCLC cells.
  • ERβ overexpression inhibited, while knockdown enhanced, cisplatin/STS-induced apoptosis and Bax activation.
  • Mitochondrial ERβ interacts with Bad, potentially suppressing Bax activation and mitochondrial translocation.

Conclusions:

  • Mitochondrial ERβ suppresses NSCLC apoptosis induced by cisplatin or STS via interaction with Bad.
  • This ERβ-Bad interaction pathway offers a novel mechanism for apoptosis regulation in NSCLC.
  • Mitochondrial ERβ represents a promising therapeutic target for NSCLC treatment.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K